Calithera Biosciences (Calithera Biosciences) Long-Term Capital Lease Obligation : $0.14 Mil (As of Dec. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Calithera Biosciences Long-Term Capital Lease Obligation?

Calithera Biosciences's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.14 Mil.

Calithera Biosciences's quarterly Long-Term Capital Lease Obligation declined from Jun. 2022 ($0.92 Mil) to Sep. 2022 ($0.53 Mil) and declined from Sep. 2022 ($0.53 Mil) to Dec. 2022 ($0.14 Mil).

Calithera Biosciences's annual Long-Term Capital Lease Obligation declined from Dec. 2020 ($4.82 Mil) to Dec. 2021 ($1.67 Mil) and declined from Dec. 2021 ($1.67 Mil) to Dec. 2022 ($0.14 Mil).

Calithera Biosciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Calithera Biosciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calithera Biosciences Long-Term Capital Lease Obligation Chart

Calithera Biosciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

6.72

4.82

1.67

0.14

Calithera Biosciences Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.67	1.30	0.92	0.53	0.14

Calithera Biosciences (OTCPK:CALA) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Calithera Biosciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Calithera Biosciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Calithera Biosciences (Calithera Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calithera Biosciences Inc (OTCPK:CALA) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080

Website

https://www.calithera.com

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.

Executives

Deepika Pakianathan	director, 10 percent owner	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Takeda Ventures, Inc.	10 percent owner	9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Keith Orford	officer: SR. VP, CLINICAL DEVELOPMENT	CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jonathan G Drachman	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Susan Molineaux	director, officer: PRESIDENT AND CEO	C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080
Christopher Molineaux	officer: SR. VP, DEVELOPMENT	CALITHERA BIOSCIENCES, 343 OYSTER POINT, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Emil Kuriakose	officer: CHIEF MEDICAL OFFICER	343 OYSTER POINT BLVD, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Millennium Pharmaceuticals Inc	10 percent owner	40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Stephanie Wong	officer: VP, FINANCE	343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO CA 94080
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104